1241916-05-1

Basic information

• Product Name: N-((4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methyl)formamide
• Synonyms: N-((4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methyl)formamide
• CAS NO: 1241916-05-1
• Molecular Weight: 376.393
• Mol File: 1241916-05-1.mol

Chemical Properties

• CAS DataBase Reference: N-((4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methyl)formamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methyl)formamide(1241916-05-1)
• EPA Substance Registry System: N-((4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methyl)formamide(1241916-05-1)

Safety Data

• Hazardous Substances Data: 1241916-05-1(Hazardous Substances Data)

Upstream product

• 1241914-67-9 (4-chloroquinazolin-2-yl)(3-fluorophenyl)methanone 
• 1241914-95-3 (R,S)-2-((benzyloxycarbonylamino)(4-fluorophenyl)methyl)-quinazolin-4-yl-2,4,6-triisopropylbenzenesulfonate 
• 1241914-92-0 (R,S)-2-(amino(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)quinazolin-4-amine 
• 1241914-72-6 (4-chloroquinazoline-2-yl)(4-fluorophenyl)methanone 
• 1241914-71-5 (4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone 
• 34632-69-4 ethyl 4-chloro-quinazoline-2-carboxylate 
• 17318-03-5 bromo(3-fluorophenyl)magnesium 
• 352-13-6 4-flourophenylmagnesium bromide 
• 109-94-4 formic acid ethyl ester 

Relevant articles and documents

ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF

Provided herein is a method of preventing, treating, or ameliorating one or more symptoms of an adenosine A3-mediated condition, disorder, or disease, with a compound of Formula I. Also provided herein is a method of preventing, treating, or ameliorating one or more symptoms of glaucoma or ocular hypertension. Further provided herein is a method of modulating the activity of an adenosine A3 receptor.

JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF

Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. (I).